Christopher Chan graduated from the Faculty of Medicine, University of Toronto in 1995. After completing his post-graduate training in internal medicine and nephrology at the University of Toronto, he pursued further training in cardiovascular physiology. He joined the Division of Nephrology at the Toronto General Hospital, University Health Network in 2002. He is the Divisional Director of Nephrology and Professor of Medicine at the University Health Network. He also holds the R Fraser Elliott Chair in Home Dialysis.
 
He has contributed over 150 peer reviewed articles and has written multiple book chapters in the field of home dialysis. He has also co-led the KDIGO consensus meeting in novel approaches in blood purification and has served as chair of the cardiac committee of the Frequent Hemodialysis Network Trials. He is presently a member of the steering committee of the ACTIVE trial.
My main research themes include: (1) cardiovascular effects of nocturnal hemodialysis; (2) effects of uremia on bone marrow biology; and (3) tele-home technology.

My research activities relate to applied clinical research in the field of intensive hemodialysis. I have coordinated and led a network of research teams dedicated to examine the clinical and basic aspects of optimal dialysis delivery. Our research has led to the awareness and clinical application of nocturnal home hemodialysis for patients with refractory hypertension and ventricular dysfunction (recommended by the Canadian Society of Nephrology clinical practice guideline and Kidney Disease Improving Global Outcomes (KDIGO) consensus statement). We have investigated the impact of increased dialysis dose and frequency on anemia management and bone marrow biology. Our work has highlighted the interplay between kidney failure and bone marrow derived stem cells, which are not only required to produce red blood cells but also necessary to maintain vascular repair and regeneration. Through a fruitful collaborative network, our research team has also examined emerging e-Health technologies to assure quality and safety of remote complex care delivery. Most recently, our multi-site virtual ward proposal has received funding to test the utility of tele-home technology in vulnerable home dialysis patients during transitions of care.
Disabil Rehabil. 2018 Jul 06;:1-15
Rodriguez AM, Komar A, Ringash J, Chan C, Davis AM, Jones J, Martino R, McEwen S
Kidney Int Rep. 2018 May;3(3):748-751
Malavade T, Cassol C, John R, Husain S, Chen CI, Chan CT
Support Care Cancer. 2018 May 29;:
Eng L, Pringle D, Su J, Shen X, Mahler M, Niu C, Charow R, Tiessen K, Lam C, Halytskyy O, Naik H, Hon H, Irwin M, Pat V, Gonos C, Chan C, Villeneuve J, Harland L, Shani RM, Brown MC, Selby P, Howell D, Xu W, Liu G, Alibhai SMH, Jones JM
Biometals. 2018 May 16;:
Chan C, Andisi VF, Ng D, Ostan N, Yunker WK, Schryvers AB
J Oncol Pharm Pract. 2018 Jan 01;:1078155218771461
Dhillon P, Amir E, Lo M, Kitchlu A, Chan C, Cochlin S, Yip P, Chen E, Lee R, Ng P
Clin J Am Soc Nephrol. 2018 Apr 16;:
Auguste BL, Al-Muhaiteeb A, Chan CT
Can J Ophthalmol. 2018 Apr;53(2):173-187
Popovic M, Chan C, Lattanzio N, El-Defrawy S, Schlenker MB
Am J Nephrol. 2018 Apr 05;47(3):208-217
Chan CT, Kaysen GA, Beck GJ, Li M, Lo J, Rocco MV, Kliger AS, FHN Trials
Semin Dial. 2018 Mar 14;:
Trinh E, Chan CT, Perl J

Pages